Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Phthalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | CA2 | P00918 | 6/20 | 0.55 |
| ▸ | CA4 | P22748 | 3/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PKLR | P30613 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 5/20 | 0.40 |
| ▸ | CES2 | O00748 | 2/20 | 0.40 |
| ▸ | CES1 | P23141 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phthalic Acid SCHEMBL32678845 | 1.00 | ALDH1A1 (0.68) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL32678846 | 1.00 | ALDH1A1 (0.68) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL32678844 | 1.00 | ALDH1A1 (0.68) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL4506080 | 0.97 | ALDH1A1 (0.65) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL3385753 | 0.97 | ALDH1A1 (0.65) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL11233274 | 0.97 | ALDH1A1 (0.65) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL30001010 | 0.97 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL28409980 | 0.97 | ALDH1A1 (0.71) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL109123 | 0.97 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL105218 | 0.97 | ALDH1A1 (0.71) | ALDH1A1KDM4EHPGDCA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1551 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114561258-B | Cleaning agent for alkaline washing tower of ethylene device | 浙江杭化科技股份有限公司 | 2023-11-17 | — | — | CN | claimed |
| CN-114561258-A | Ethylene unit alkaline washing tower detergent | 浙江杭化科技股份有限公司 | 2022-05-31 | — | — | CN | claimed |
| US-20260146092-A1 | DUAL SPECIFICITY ANTIBODIES TO HUMAN PD-L1 AND PD-L2 AND METHODS OF USE THEREFOR | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-05-28 | — | — | US | disclosed |
| US-12637518-B2 | Dual specificity antibodies to human PD-L1 and PD-L2 and methods of use therefor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-05-26 | — | — | US | disclosed |
| WO-2026102432-A1 | HUMAN ANTIBODIES TO MARBURG VIRUS AND METHODS OF USE THEREFOR | VANDERBILT UNIVERSITY (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260109765-A1 | MULTI-SPECIFIC ANTIBODIES WITH AFFINITY FOR HUMAN A33 ANTIGEN AND DOTA METAL COMPLEX AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4720675-A2 | HUMAN MONOCLONAL ANTIBODIES FOR HUMAN PARAINFLUENZA VIRUS TYPE 3 | Vanderbilt University (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12596122-B2 | LILRB2 antibodies and uses thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4705352-A1 | BDCA2-TARGETING ANTIBODIES AND USES THEREOF | Inmagene Pte. Ltd. (SG) | 2026-03-11 | — | — | EP | disclosed |
| EP-4698566-A2 | AGNONISTIC ANTIBODIES TARGETING JAML | La Jolla Institute for Immunology (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12559545-B2 | Human hendra virus and nipah virus antibodies and methods of use therefor | VANDERBILT UNIVERSITY (US) | 2026-02-24 | — | — | US | disclosed |
| EP-0589840-A1 | Reshaped monoclonal antibodies against an immunoglobulin isotype | CIBA-GEIGY AG (CH) | 1994-03-30 | — | — | EP | disclosed |
| US-5296352-A | Monoclonal antibodies directed against complexes formed by thrombin and hirudin | CIBA-GEIGY CORPORATION (US) | 1994-03-22 | — | — | US | disclosed |
| WO-1993019180-A1 | GENETICALLY ENGINEERED ANTIBODIES | CIBA-GEIGY AG (CH) | 1993-09-30 | — | — | WO | disclosed |
| EP-0519866-A1 | Novel anti-HIV antibodies | CIBA-GEIGY AG (CH) | 1992-12-23 | — | — | EP | disclosed |
| EP-0498767-A2 | Chimeric antiidiotypic monoclonal antibodies | CIBA-GEIGY AG (CH) | 1992-08-12 | — | — | EP | disclosed |
| EP-0479721-A2 | Monoclonal antibodies directed against complexes formed by thrombin and thrombin inhibitors | CIBA-GEIGY AG (CH) | 1992-04-08 | — | — | EP | disclosed |
| EP-0428485-A1 | Novel antiidiotypic monoclonal antibodies | NEW YORK MEDICAL COLLEGE (US) | 1991-05-22 | — | — | EP | disclosed |
| EP-0412050-A1 | Novel cytokines | CIBA-GEIGY AG (CH) | 1991-02-06 | — | — | EP | disclosed |
| EP-0392976-A1 | Monoclonal antibodies to tetracyclic compounds, processes for their production, and applications | CIBA-GEIGY AG (CH) | 1990-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12596122-B2 | LILRB2 antibodies and uses thereof | FCGR3B, IL2RA, LIFR | PTGS2 4551/4885ALDH1A1 4032/4885KDM4E 3095/4885 |
| US-20260109765-A1 | MULTI-SPECIFIC ANTIBODIES WITH AFFINITY FOR HUMAN A33 ANTIGEN AND DOTA METAL COMPLEX AND USES THEREOF | F13A1, CA13, MICA | PTGS2 4834/4885ALDH1A1 3814/4885KDM4E 2587/4885 |
| US-12637518-B2 | Dual specificity antibodies to human PD-L1 and PD-L2 and methods of use therefor | PDCD1LG2, CD274, PDCD1 | PTGS2 4401/4885ALDH1A1 2813/4885KDM4E 774/4885 |
| US-20260146092-A1 | DUAL SPECIFICITY ANTIBODIES TO HUMAN PD-L1 AND PD-L2 AND METHODS OF USE THEREFOR | PDCD1LG2, PDCD1, CD274 | PTGS2 4771/4885ALDH1A1 2835/4885KDM4E 1991/4885 |
| US-12559545-B2 | Human hendra virus and nipah virus antibodies and methods of use therefor | VSIG8, IGSF11, NIPSNAP1 | PTGS2 3050/4885ALDH1A1 3333/4885KDM4E 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.